For decades, U.S.policymakers have highlighted the vulnerabilities of relying on foreign supply chains for essential medicines.
Yet over 70% of the primary manufacturing facilities for prescriptions filled in the United States remain outside our borders.Over time, a suffocating web of state and federal regulations meant that companies investing millions or billions to build facilities in the U.S.
would see those investments sit idle for up to 14 months waiting for standard post-construction reviews.This paralysis has driven supply chains further overseas, hurting the Americans who rely on life-saving cures and treatments.When critical supply chains are anchored half a world away, American patients are left exposed to dangerous shortages and American workers are stripped of high-paying employment opportunities.President Donald Trump prioritized solving this problem by signing Executive Order 14293, "Regulatory Relief to Promote Domestic Production of Critical Medicines," directing the FDA to cut red tape, incentivize domestic manufacturing and secure medicines for American patients.
The FDA took that directive urgently.Moving into mid-July, we are aggressively executing on multiple fronts to spark a domestic manufacturing renaissance – removing regulatory roadblocks and creating an environment where American production can outcompete the rest of the world.TRUMP’S DRUG PRICE WAR WITH EUROPE AIMS TO MAKE THINGS CHEAPER FOR AMERICANSTo rev up our domestic pharmaceutical manufacturing base from the ground up, the FDA recently launched the PreCheck Pilot Program.
Designed to clear the hurdles that stall new manufacturing facility builds in the U.S., this program is already unleashing a historic wave of domestic job creation, proving we can secure our health while building a powerhouse economy.Eli Lilly is one of seven firms working with the FDA to reshore key medical manufacturing.FILE: In this May 2020 photo provided by Eli Lilly, researchers prepare cells to pr...